Post-Authorization Study Evaluating Safety Of Tigecycline (HORUS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00827541
First received: January 20, 2009
Last updated: December 23, 2011
Last verified: December 2011
Results First Received: December 23, 2011  
Study Type: Observational
Study Design: Observational Model: Cohort;   Time Perspective: Prospective
Conditions: Intra-Abdominal Infections
Skin Disease, Infectious
Soft Tissues Infections
Intervention: Drug: Tigecycline

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Complicated Skin and Soft-tissue Infections Participants with Complicated Skin and Soft-tissue Infections (cSSTI) received tigecycline (Tygacil) at an initial dose of 100 milligram (mg) followed by 50 mg every 12 hours intravenously for 5 to 14 days based on local prescribing practices.
Complicated Intra-Abdominal Infections Participants with Complicated Intra-Abdominal Infections (cIAI) received tigecycline (Tygacil) at an initial dose of 100 mg followed by 50 mg every 12 hours intravenously for 5 to 14 days based on local prescribing practices.

Participant Flow:   Overall Study
    Complicated Skin and Soft-tissue Infections     Complicated Intra-Abdominal Infections  
STARTED     19     96  
COMPLETED     15     85  
NOT COMPLETED     4     11  
Exitus                 1                 8  
Unspecified                 1                 3  
Pathogen not susceptible                 1                 0  
Lack of effectiveness                 1                 0  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Complicated Skin and Soft-tissue Infections Participants with Complicated Skin and Soft-tissue Infections (cSSTI) received tigecycline (Tygacil) at an initial dose of 100 milligram (mg) followed by 50 mg every 12 hours intravenously for 5 to 14 days based on local prescribing practices.
Complicated Intra-Abdominal Infections Participants with Complicated Intra-Abdominal Infections (cIAI) received tigecycline (Tygacil) at an initial dose of 100 mg followed by 50 mg every 12 hours intravenously for 5 to 14 days based on local prescribing practices.
Total Total of all reporting groups

Baseline Measures
    Complicated Skin and Soft-tissue Infections     Complicated Intra-Abdominal Infections     Total  
Number of Participants  
[units: participants]
  19     96     115  
Age  
[units: years]
Mean ± Standard Deviation
  61.53  ± 11.01     59.27  ± 16.47     59.64  ± 15.68  
Gender  
[units: participants]
     
Female     5     47     52  
Male     14     49     63  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)   [ Time Frame: Up to Week 12 ]

2.  Secondary:   Percentage of Participants With Clinical Response of Cure   [ Time Frame: Days 2-5, 7-14 and 21-28 during treatment and Days 1-3 after end of treatment ]

3.  Secondary:   Number of Participants With Susceptible Microbiological Pathogens   [ Time Frame: Baseline and Week 12 ]

4.  Secondary:   Number of Participants With Eradication of Microbiological Pathogens   [ Time Frame: Week 12 ]


  Serious Adverse Events


  Other Adverse Events


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Limitations and Caveats
Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.  


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided by Pfizer

Publications automatically indexed to this study:

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00827541     History of Changes
Other Study ID Numbers: B1811048, 3074A1-4401
Study First Received: January 20, 2009
Results First Received: December 23, 2011
Last Updated: December 23, 2011
Health Authority: Spain: Ministry of Health